Spots Global Cancer Trial Database for hodgkin's lymphoma
Every month we try and update this database with for hodgkin's lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas | NCT02259556 | Hodgkin's Lymph... Non-Hodgkin's L... | CART30 | 16 Years - 80 Years | Chinese PLA General Hospital | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Safety of Romiplostim (Nplate®) Following UCBT | NCT02046291 | Hematologic Mal... | Romiplostim | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory | NCT00879528 | Hodgkin's Lymph... | Patients with n... Patients with p... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma | NCT01037478 | Hodgkin's Lymph... | Resminostat (4S... | 18 Years - | 4SC AG | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | NCT01767766 | Non-Hodgkin's L... Chronic Lymphoc... Peripheral T-Ce... Hodgkin's Lymph... | TGR-1202 | 18 Years - | TG Therapeutics, Inc. | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | NCT00388349 | Hodgkin Disease Hodgkin's Lymph... Lymphoma | Gemcitabine Vinorelbine Carmustine Etoposide Cyclophosphamid... Autologous HCT | 18 Years - 70 Years | Stanford University | |
| Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A | NCT01858922 | Hodgkin Disease | ABVE-PC DECA | - | Baylor College of Medicine | |
| Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A | NCT01858922 | Hodgkin Disease | ABVE-PC DECA | - | Baylor College of Medicine | |
| A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | NCT00283439 | Chemotherapy-In... Hodgkin's Lymph... Non-Hodgkin's L... Cancer Oncology Thrombocytopeni... | AMG 531 | 18 Years - | Amgen | |
| Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | NCT00273936 | Acute Leukemia Chronic Leukemi... Multiple Myelom... Hodgkin's Lymph... Non-Hodgkin's L... Waldenstrom's M... | AVN-944 capsule... | 18 Years - | Vertex Pharmaceuticals Incorporated | |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | NCT01421173 | Lymphoma | Vorinostat Gemcitabine Busulfan Melphalan Stem Cell Infus... Rituximab G-CSF Palifermin Dexamethasone a... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation | NCT01203020 | Hodgkin's Lymph... Non-Hodgkin's L... | Busulfan Fludarabine | 18 Years - 70 Years | West Virginia University | |
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | NCT00520130 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's D... Acute Leukemia Multiple Myelom... | Rituximab Cyclosporine Allogenic stem ... Conditioning Ch... TMS FLAG EPOCH-F Alemtuzumab | 18 Years - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma | NCT01788839 | Breast Cancer Lymphoma Hodgkin's Lymph... | surveys Blood draw Transvaginal ul... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | NCT02593123 | Hodgkin's Lymph... Lymphoid Leukem... Lymphoma Leukemia Myeloma Acute Lymphocyt... Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... Chronic Myeloge... Myelodysplastic... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Recurrent Chron... Recurrent Chron... Acute Myelogeno... | mycophenolate m... Sargramostim Filgrastim | 18 Years - 74 Years | Virginia Commonwealth University | |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | NCT00388349 | Hodgkin Disease Hodgkin's Lymph... Lymphoma | Gemcitabine Vinorelbine Carmustine Etoposide Cyclophosphamid... Autologous HCT | 18 Years - 70 Years | Stanford University | |
| Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | NCT01983761 | Blood And Marro... Leukemia Lymphoma Transplantation... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Lymph... | Fludarabine, Cl... Fludarabine, Me... | 1 Year - 80 Years | Targazyme, Inc. | |
| Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma | NCT00061672 | Lymphoma, Non-H... Hodgkin's Lymph... | ABT-510 - Throm... | 18 Years - | Abbott | |
| Autologous Transplant in HIV Patients (BMT CTN 0803) | NCT01141712 | Lymphoma HIV | Autologous tran... BCNU Etoposide Cytarabine Melphalan | 15 Years - | Medical College of Wisconsin | |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | NCT00809276 | Lymphoma Multiple Myelom... Leukemia Myelodysplastic... | Busulfan, Fluda... | - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma | NCT00359892 | Hodgkin's Lymph... | Obatoclax mesyl... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | NCT02408042 | Lymphoma Hodgkin's Lymph... Non-hodgkin's L... | Pembrolizumab Etoposide Ifosfamide Mesna Carboplatin Brentuximab ved... Rituximab | 18 Years - | Western Regional Medical Center | |
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | NCT01884428 | Hodgkin's Lymph... | panobinostat Ifosfamide Gemcitabine Vinorelbine Prednisolone | 18 Years - 65 Years | Istituto Clinico Humanitas | |
| Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma | NCT00428688 | Hodgkin's Lymph... | 18 Years - 50 Years | Sheba Medical Center | ||
| A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma | NCT01877005 | Hodgkin's Lymph... | Ruxolitinib | 18 Years - | The Lymphoma Academic Research Organisation | |
| Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | NCT00276159 | Acute Lymphobla... Acute Myeloid L... Non-Hodgkin's L... Hodgkin's Lymph... Multiple Myelom... Chronic Lymphoc... | 852A | - | Masonic Cancer Center, University of Minnesota | |
| Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma | NCT00792467 | Hodgkin's Lymph... | ITF2357 | 18 Years - | Italfarmaco | |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | NCT05337735 | Microsatellite ... Peritoneal Meso... Extrapulmonary ... Neuroendocrine ... Cervical Carcin... Hodgkin's Lymph... Pleural Mesothe... Small Cell Lung... | XmAb20717 | 18 Years - | M.D. Anderson Cancer Center | |
| FLT PET: A Pilot Study in Lymphoma Patients | NCT04028804 | Hodgkin's Lymph... Non-Hodgkin's L... | FDG PET FLT PET | 1 Day - 18 Years | The Hospital for Sick Children | |
| Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | NCT00520130 | Myelodysplastic... Hodgkin's Lymph... Non-Hodgkin's D... Acute Leukemia Multiple Myelom... | Rituximab Cyclosporine Allogenic stem ... Conditioning Ch... TMS FLAG EPOCH-F Alemtuzumab | 18 Years - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | NCT00670592 | Non-Hodgkin's L... Hodgkin's Lymph... | HCD122 | 18 Years - | Novartis | |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | NCT02576496 | Hematological M... Multiple Myelom... Hodgkin's Lymph... Cutaneous T Cel... | Tinostamustine | 18 Years - | Mundipharma Research Limited | |
| Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | NCT00984165 | Hodgkin's Lymph... Non-Hodgkin's L... Chronic Lymphoc... Multiple Myelom... | Single fraction... Donor Lymphocyt... Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London | |
| FLT PET: A Pilot Study in Lymphoma Patients | NCT04028804 | Hodgkin's Lymph... Non-Hodgkin's L... | FDG PET FLT PET | 1 Day - 18 Years | The Hospital for Sick Children | |
| Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy | NCT02404818 | Hodgkin's Lymph... | Cardiac Magneti... Echocardiogram | 18 Years - | University of Florida | |
| Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL | NCT01358747 | Hodgkin's Lymph... | BEACOPPesc BEACOPPesc - AB... | 16 Years - 60 Years | Centre Hospitalier Universitaire Dijon | |
| Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma | NCT00816959 | Hodgkin's Lymph... | R-mabHDI and AB... ABVD | 16 Years - 65 Years | American Scitech International | |
| Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions | NCT01399931 | Hodgkin's Lymph... | 18 Years - 60 Years | Ospedale Santa Croce-Carle Cuneo | ||
| Pegfilgrastim PBPC Mobilization Study | NCT00066092 | Lymphoma Hodgkin's Lymph... Non-Hodgkin's L... Hematology Oncology | pegfilgrastim 1... filgrastim pegfilgrastim 6... | 18 Years - | Amgen | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | NCT02613598 | Hodgkin's Lymph... Lymphoma, Non-H... | Bortezomib Ruxolitinib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma | NCT00061672 | Lymphoma, Non-H... Hodgkin's Lymph... | ABT-510 - Throm... | 18 Years - | Abbott | |
| Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma | NCT01884428 | Hodgkin's Lymph... | panobinostat Ifosfamide Gemcitabine Vinorelbine Prednisolone | 18 Years - 65 Years | Istituto Clinico Humanitas | |
| Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | NCT00626626 | Leukemia Myelodysplastic... Chronic Myeloge... Lymphoma Hodgkin's Lymph... Multiple Myelom... | Clofar, Cycloph... Clofar, Cycloph... | 18 Years - 75 Years | Milton S. Hershey Medical Center | |
| Reduced Intensity Double Umbilical Cord Blood Transplantation | NCT01408563 | Non-Hodgkin's L... Hodgkin's Lymph... Multiple Myelom... Chronic Lymphoc... Acute Myelogeno... | Fludarabine Melphalan Total Body Radi... Cord Blood | 18 Years - 70 Years | Massachusetts General Hospital | |
| Low Dose Chest Computed Tomography (CT) Screening | NCT01180010 | Hodgkin's Lymph... | Low Dose CT | 18 Years - | University Health Network, Toronto | |
| Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies | NCT00476229 | Lymphoma Leukemia | Thymoglobulin Total Lymphoid ... Peripheral Bloo... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies | NCT00476229 | Lymphoma Leukemia | Thymoglobulin Total Lymphoid ... Peripheral Bloo... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | NCT02576496 | Hematological M... Multiple Myelom... Hodgkin's Lymph... Cutaneous T Cel... | Tinostamustine | 18 Years - | Mundipharma Research Limited | |
| Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | NCT02059239 | Hodgkin's Lymph... Non-Hodgkin's L... | Bendamustine Carmustine Etoposide Melphalan Cytarabine Alemtuzumab Autologous Stem... Allogeneic Stem... Rituximab | 18 Years - | Weill Medical College of Cornell University | |
| High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients | NCT00784537 | Hodgkin's Lymph... | ABVD ABVD and Radiot... | 18 Years - 70 Years | Fondazione Italiana Linfomi - ETS | |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | NCT01135329 | Lymphoma Leukemia Myelodysplastic... | Fludarabine Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma | NCT01578967 | Hodgkin Lymphom... | Brentuximab ved... ABVD | 18 Years - 60 Years | UNC Lineberger Comprehensive Cancer Center | |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | NCT00881946 | Hematologic Mal... | GSK21110183 | 18 Years - | Accenture | |
| Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | NCT01169636 | Hodgkin's Lymph... | Panobinostat Ifosfamide Mesna Carboplatin Etoposide Pegfilgrastim | 16 Years - | M.D. Anderson Cancer Center | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | NCT03776864 | Hodgkin's Lymph... | Pembrolizumab Umbralisib | 18 Years - | University of Washington | |
| Low Dose Chest Computed Tomography (CT) Screening | NCT01180010 | Hodgkin's Lymph... | Low Dose CT | 18 Years - | University Health Network, Toronto | |
| Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients | NCT01884441 | Hodgkin's Lymph... | Bendamustine Gemcitabine Vinorelbine | 18 Years - | Istituto Clinico Humanitas | |
| Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | NCT01032148 | Hodgkin's Lymph... Non-Hodgkin's L... | LBH589 | 18 Years - | Roswell Park Cancer Institute | |
| Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | NCT00670592 | Non-Hodgkin's L... Hodgkin's Lymph... | HCD122 | 18 Years - | Novartis | |
| FLT PET: A Pilot Study in Lymphoma Patients | NCT04028804 | Hodgkin's Lymph... Non-Hodgkin's L... | FDG PET FLT PET | 1 Day - 18 Years | The Hospital for Sick Children | |
| Nonmyeloablative Allogeneic Transplant | NCT01272817 | Aplastic Anemia Paroxysmal Noct... Acute Myelogeno... Acute Lymphocyt... Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Hodgkin's Lymph... Non-Hodgkin's L... Mantle Cell Lym... Multiple Myelom... Waldenstrom Mac... Breast Cancer Renal Cell Carc... Melanoma Sarcoma Ovarian Cancer Thymoma | Nonmyeloablativ... Nonmyeloablativ... | 18 Years - 72 Years | Scripps Health | |
| Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL) | NCT01300156 | Hodgkin's Lymph... | Oxaliplatin-bas... | 18 Years - 75 Years | National Cancer Center, Korea | |
| Reduced Intensity Double Umbilical Cord Blood Transplantation | NCT01408563 | Non-Hodgkin's L... Hodgkin's Lymph... Multiple Myelom... Chronic Lymphoc... Acute Myelogeno... | Fludarabine Melphalan Total Body Radi... Cord Blood | 18 Years - 70 Years | Massachusetts General Hospital | |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | NCT02722733 | Hodgkin's Lymph... Non-Hodgkin's L... | G-CSF (filgrast... Cytosine arabin... | 18 Years - 65 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT | NCT01478191 | Hodgkin's Lymph... | 18 Years - | Fondazione Italiana Linfomi - ETS | ||
| Communication Skills Intervention to Promote Transition Into Survivorship | NCT01483664 | Hodgkin's Lymph... Diffuse Large B... | 18 Years - | Memorial Sloan Kettering Cancer Center | ||
| Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers | NCT01597219 | Hodgkin's Lymph... Non-Hodgkin's L... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Acquired Bone M... Other Haematolo... | Reduced intensi... Myeloablative h... | 16 Years - 70 Years | University College, London | |
| Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma | NCT02722733 | Hodgkin's Lymph... Non-Hodgkin's L... | G-CSF (filgrast... Cytosine arabin... | 18 Years - 65 Years | Maria Sklodowska-Curie National Research Institute of Oncology | |
| Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell Transplant | NCT00510315 | Leukemia Hodgkin's Lymph... Non-Hodgkin's L... Myelodysplastic... | Questionnaires,... | 18 Years - 49 Years | Memorial Sloan Kettering Cancer Center | |
| Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET | NCT00188149 | Hodgkin Disease | Combined chemot... Radiation thera... | 16 Years - 75 Years | University Hospital Carl Gustav Carus | |
| Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | NCT01169636 | Hodgkin's Lymph... | Panobinostat Ifosfamide Mesna Carboplatin Etoposide Pegfilgrastim | 16 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
